Evaluate the Mediators of Sensitivity and Resistance to Nivolumab Plus Ipilimumab in Patients With Advanced NSCLCs
Conditions
- Advanced Stage Non-small Cell Lung Cancer
Interventions
- DRUG: nivolumab
- DRUG: pilimumab
Sponsor
Memorial Sloan Kettering Cancer Center
Collaborators